PRA Expands Operations in Europe

RALEIGH, N.C., May 21, 2012 /PRNewswire/ --  PRA, a leading Clinical Research Organization, announces the expansion of operations in The Netherlands (NL) and the United Kingdom (UK) to accommodate staff growth and strong client demand for our Phase IIa-IIIb service offerings.

Located in the thriving city of Utrecht, NL, this new Dutch facility will host 20+ employees and is the first PRA office in that region to primarily support Product Registration trials. Staff from our three other NL locations (Groningen, Zuidlaren and Assen) support early development and lab studies.

Previously, our Product Registration staff members in The Netherlands were either home-based or shared facilities with our Mechelen, Belgium employees. "But to better share best practices among employees, we felt that it was now necessary to provide a permanent office for the increasing Dutch Product Registration team," said PRA's Frank van de Wijngaert, Vice President and General Partner.

Also this month, PRA's 240+ employees in Reading, UK relocated to a larger, PRA-designed facility that offers additional room for increasing headcounts and provides modern facilities for client and project team meetings. The location also offers a first-class business park environment with excellent transportation links.

Since 2009, PRA has opened nine new offices in Europe, demonstrating our commitment to meeting our clients' diverse needs in a dynamic clinical trials environment.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email [email protected] or call our Global Headquarters.

SOURCE PRA